TriSalus Life Sciences, Inc. has announced its financial results for the third quarter of 2026, revealing a notable increase in revenue and a positive outlook for the future. The company reported $12.9 million in revenue for the quarter, driven by an expanded commercial organization and increasing market penetration. This growth comes as TriSalus also revised its revenue guidance for the year to between $46 million and $48 million, reflecting confidence in its operational strategy and market conditions.
Mary Szela, President and Chief Executive Officer of TriSalus, emphasized the company’s achievements during the quarter, stating, "The third quarter marked an important period of growth and expansion for TriSalus. We drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice. This clearance allows us to address the full range of vessels encountered in liver embolization procedures going forward."
The announcement was made on November 10, 2026, as part of a Current Report filed with the SEC, detailing the company's financial performance and operational updates. The filing is accessible under accession number 0001628280-26-072513.
Background
TriSalus Life Sciences, Inc. operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company trades on the Nasdaq under the ticker symbols TLSI and TLSIW. It focuses on integrating novel delivery technology with standard care therapies, particularly in oncology.
What the Filing Says
According to the filing, TriSalus reported third-quarter revenue of $12.9 million, an 11.3% increase compared to the same period in 2025. The company also noted that it has revised its revenue guidance for 2026 to a range of $46 million to $48 million. The press release attached to the filing highlights the favorable reimbursement policies finalized by the Centers for Medicare & Medicaid Services (CMS) for procedures using Pressure-Enabled Drug Delivery (PEDD) in 2027.
Impact
This financial update may significantly affect TriSalus's stakeholders, including investors, employees, and healthcare providers. The positive revenue growth and favorable reimbursement policies could enhance the company's market position and operational capabilities, potentially leading to increased investment and expansion opportunities.
What's Next
Following this filing, TriSalus is expected to continue its efforts to expand its commercial footprint and educate healthcare providers on the utilization of its products. The filing does not specify any immediate next steps beyond the ongoing operational strategies discussed.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










